Related Experiment Video
Updated: Jan 20, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Nutraceutical targeting of TLR4 signaling has potential for prevention of cancer cachexia
Mark F McCarty1, Simon Iloki-Assanga2, Lidianys Maria Lewis Lujany2
1Catalytic Longevity, San Diego, California, USA.
Abstract:
The mechanisms underlying cancer cachexia - the proximate cause of at least 20% of cancer-related deaths - have until recently remained rather obscure. New research, however, clarifies that cancers evoking cachexia release microvesicles rich in heat shock proteins 70 and 90, and that these extracellular heat shock proteins induce cachexia by serving as agonists for toll-like receptor 4 (TLR4) in skeletal muscle, macrophages, and adipocytes. Hence, safe nutraceutical measures which can down-regulate TLR4 signaling can be expected to aid prevention and control of cancer cachexia. There is reason to suspect that phycocyanobilin, ferulic acid, glycine, long-chain omega-3s, green tea catechins, β-hydroxy-β-methylbutyrate, carnitine, and high-dose biotin may have some utility in this regard.
Insights
Cancer cachexia, a major cause of cancer deaths, is triggered by microvesicles from tumors. These microvesicles activate toll-like receptor 4 (TLR4), leading to muscle and fat loss. Nutraceuticals targeting TLR4 may help manage cachexia.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Cancer cachexia is a significant contributor to cancer-related mortality, with its underlying mechanisms previously unclear.
- Recent findings illuminate the role of tumor-released microvesicles in cachexia development.
Purpose of the Study:
- To elucidate the molecular mechanisms by which cancers induce cachexia.
- To identify potential therapeutic targets for preventing and managing cancer cachexia.
Main Methods:
- Analysis of microvesicles released by cachexia-evoking cancers.
- Investigation of the role of heat shock proteins (HSPs) 70 and 90 in microvesicles.
- Assessment of the activation of toll-like receptor 4 (TLR4) signaling in target cells (skeletal muscle, macrophages, adipocytes).
Main Results:
- Cancers causing cachexia release microvesicles containing heat shock proteins 70 and 90.
- These extracellular heat shock proteins act as agonists for toll-like receptor 4 (TLR4).
- TLR4 activation in skeletal muscle, macrophages, and adipocytes mediates cachexia.
Conclusions:
- Tumor-derived microvesicles carrying HSPs activate TLR4, driving cancer cachexia.
- Down-regulating TLR4 signaling presents a potential therapeutic strategy for cancer cachexia.
- Specific nutraceuticals, including phycocyanobilin and omega-3 fatty acids, may modulate TLR4 signaling and aid in cachexia management.
Related Concept Videos
Cancer Prevention
Some...
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Synaptic Signaling
What is Cell Signaling?
Endocrine Signaling

